Coadministration of memantine with acetylcholinesterase inhibitors: preclinical and clinical evidence

Toxicology of Organophosphate & Carbamate Compounds

Volumn , Issue , 2006, Pages 35-46

  Dekundy, Andrzej ^a  

^a MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33847143936     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088523-7/50005-3     Document Type: Chapter

References (90)

1. Antonijevic B., Maksimovic M., Kilibarda V., Stojiljkovic M.P., Nedeljkovic M., Milovanovic Z.A., Djukic M. Efficacy of oximes and adamantanes against soman poisoning in mice. Proc. Chem. Biol. Med. Treat. Symp., 3rd, Spiez, Switzerland, May 7-12, 2000 2002.
2. Blanpied T.A., Boeckman F.A., Aizenman E., Johnson J.W. Trapping channel block of NMDA-activated responses by amantadine and memantine. J. Neurophysiol. 1997, 77:309-323.
3. Bormann J. Memantine is a potent blocker of N-methyl-d-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 1989, 166:591-592.
4. Bresink I., Danysz W., Parsons C.G., Mutschler E. Different binding affinities of NMDA receptor channel blockers in various brain regions-Indication of NMDA receptor heterogeneity. Neuropharmacology 1995, 34:533-540.
5. Carlton S.M., Rees H., Gondesen K., Tsuruoka M., Willis W.D. Behavioral and electrophysiological effects of memantine in a primate model of peripheral neuropathy. Soc. Neurosci. Abs. 1994, 20(No. 568.18).
6. Carlton S.M., Rees H., Tsuruoka M., Willis W.D. Memantine attenuates responses of spinothalamic tract cells to cutaneous stimulation in neuropathic monkeys. Eur. J. Pain 1998, 2:229-238.
7. Chen H.S., Wang Y.F., Rayudu P.V., Edgecomb P., Neill J.C., Segal M.M., Lipton S.A., Jensen F.E. Neuroprotective concentrations of the N-methyl-d-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 1998, 86:1121-1132.
8. Dai X.F., Zhou Z.J., Gu X.A., Sun Y.G., Zheng G., Zheng J. Protective effect of memantine on N-methyl-d-aspartate receptor in dichlorvos-poisoned rat brain. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2004, 22:11-14.
9. Danysz W., Parsons C.G. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: Preclinical evidence. Int. J. Geriatr. Psychiatr. 2003, 18(Suppl. 1):S23-S32.
10. Danysz W., Gossel M., Zajaczkowski W., Dill D., Quack G. Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine. J. Neural. Transm. Park. Dis. Dement. Sect. 1994, 7:155-166.
11. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., Quack G. Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-Preclinical studies. Neurosci. Biobehav. Rev. 1997, 21:455-568.
12. Danysz W., Parsons C.G., Möbius H.J., Stöffler A., Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease-A unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity, Icol. Res. 2000, 2:85-97.
13. Dekundy A., Gupta R., Danysz W., Quack G. Lack of interaction of memantine with antidementia AChE inhibitors in rat brain: Mechanistic based therapeutic considerations. Toxicol. Appl. Pharmacol. 2004, 197:366.
14. Ditzler K. Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. Arzneimittelforschung 1991, 41:773-780.
15. Dubner R., Ruda M.A. Activity-dependent neuronal plasticity following tissue injury and inflammation. Trends Neurosci. 1992, 15:96-103.
16. Eisenberg E., LaCross S., Strassman A.M. The clinically tested N-methyl-d-aspartate receptor antagonist memantine blocks and reverses thermal hyperalgesia in a rat model of painful mononeuropathy. Neurosci. Lett. 1995, 187:17-20.
17. Enz A., Gentsch C. Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. Neuropharmacology 2004, 47:408-413.
18. 2+ in hippocampal slices. Neuropharmacology 1999, 38:1253-1259.
19. Frankiewicz T., Potier B., Bashir Z.I., Collingridge G.L., Parsons C.G. Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br. J. Pharmacol. 1996, 117:689-697.
20. Gerzon K., Krumkalns E.V., Brindle R.L., Marshall F.J., Root M.A. The adamantyl group in medicinal agents. 1. Hypoglycemic arylsulfonyl-N'-adamantylureas. J. Med. Chem. 1963, 122:760-763.
21. Giulian D., Wendt E., Vaca K., Noonan C.A. The envelope glycoprotein of human immunodeficiency virus type-1 stimulates release of neurotoxins from monocytes. Proc. Natl. Acad. Sci. USA 1993, 90:2769-2773.
22. Görtelmeyer R., Erbler H. Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittelforschung 1992, 42:904-913.
23. Graham S., Lee G., Möbius H.J., McDonald S., Winblad B. Efficacy and tolerability of memantine in nursing home patients with moderate to severe dementia of the Alzheimer's type. 43rd annual New Clinical Drug Evaluation Unit (NCDEU) meeting 2003, 224.
24. Greenamyre J.T., Maragos W.F., Albin R.L., Penney J.B., Young A.B. Glutamate transmission and toxicity in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatr. 1988, 12:421-430.
25. Grutzendler J., Morris J.C. Cholinesterase inhibitors for Alzheimer's disease. Drugs 2001, 61:41-52.
26. Gupta R.C. Carbofuran toxicity. J. Toxicol. Environ. Health 1994, 43:383-418.
27. Gupta R.C. Mechanistic and clinical approaches in antidotal treatment with memantine and atropine against oxamyl and methomyl-acute toxicity. Ind. J. Toxicol. 1994, 1:1-10.
28. Gupta R.C., Dekundy A. Memantine does not influence AChE inhibition in rat brain by donepezil or rivastigmine but does with DFP and metrifonate in in vivo studies. Drug Dev. Res. 2005, 64:71-81.
29. Gupta R.C., Dettbarn W.-D. Potential of memantine, d-tubocurarine, and atropine in preventing acute toxic myopathy induced by organophosphate nerve agents-Soman, sarin, tabun and VX. Neurotoxicology 1992, 13:649-661.
30. Gupta R.C., Goad J.T. Role of high-energy phosphates and their metabolites in protection of carbofuran-induced biochemical changes in diaphragm muscle by memantine. Arch. Toxicol. 2000, 74:13-20.
31. Gupta R.C., Kadel W.L. Prevention and antagonism of acute carbofuran intoxication by memantine and atropine. J. Toxicol. Environ. Health 1989, 28:111-122.
32. Gupta R.C., Kadel W.L. Novel effects of memantine in antagonizing acute aldicarb toxicity: Mechanistic and applied considerations. Drug. Dev. Res. 1991, 24:329-341.
33. Gupta R.C., Kadel W.L. Methyl parathion acute toxicity: Prophylaxis and therapy with memantine and atropine. Arch. Int. Pharmacodyn. Ther. 1990, 305:208-221.
34. Gupta R.C., Milatovic D., Dettbarn W.-D. Involvement of nitric oxide in myotoxicity produced by diisopropyl-phosphorofluoridate (DFP)-induced muscle hyperactivity. Arch. Toxicol. 2002, 76:715-726.
35. Gupta R.C., Dekundy A., Danysz W., Quack G. Memantine does not interfere with donepezil or rivastigmine-induced inhibition of AChE in rat cortex and hippocampus. J. Neurochem. 2004, 90(Suppl. 1):43.
36. Harkany T., Abraham I., Timmerman W., Laskay G., Toth B., Sasvari M., Konya C., Sebens J.B., Korf J., Nyakas C., Zarandi M., Soos K., Penke B., Luiten P.G. Beta-amyloid neurotoxicity is mediated by a glutamatetriggered excitotoxic cascade in rat nucleus basalis. Eur. J. Neurosci. 2000, 12:2735-2745.
37. Hartmann S., Möbius H.J. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int. Clin. Psychopharmacol. 2003, 18:81-85.
38. Holter S.M., Danysz W., Spanagel R. Evidence for alcohol anti-craving properties of memantine. Eur. J. Pharmacol. 1996, 314:R1-R2.
39. Ibach B., Haen E. Acetylcholinesterase inhibition in Alzheimer's disease. Curr. Pharm. Design 2004, 10:231-251.
40. Jacobsson S.O., Fowler C.J. Dopamine and glutamate neurotoxicity in cultured chick telencephali cells: Effects of NMDA antagonists antioxidants and MAO inhibitors. Neurochem. Int. 1999, 34:49-62.
41. Karcz-Kubicha M., Lorenz B., Danysz W. GlycineB antagonists and partial agonists in rodent models of Parkinson's disease-Comparison with uncompetitive N-methyl-d-aspartate receptor antagonist. Neuropharmacology 1999, 38:109-119.
42. Kashiwagi K., Masuko T., Nguyen C.D., Kuno T., Tanaka I., Igarashi K., Williams K. Channel blockers acting at N-methyl-d-aspartate receptors: Differential effects of mutations in the vestibule and ion channel pore. Mol. Pharmacol. 2002, 61:533-545.
43. KeilhoffG., Wolf G. Memantine prevents quinolinic acid-induced hippocampal damage. Eur. J. Pharmacol. 1992, 219:451-454.
44. Kornhuber J., Quack G. Cerebrospinal fluid and serum concentrations of the N-methyl-d-aspartate (NMDA) receptor antagonist memantine in man. Neurosci. Lett. 1995, 195:137-139.
45. Kornhuber J., Bormann J., Hubers M., Rusche K., Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: A human postmortem, brain study. Eur. J. Pharmacol. 1991, 206:297-300.
46. Li L., Sengupta A., Haque N., Grundke-Iqbal I., Iqbal K. Memantine inhibits and reverses the Alzheimer type abnormal phosphorylation of tau and associated neurodegeneration. FEBS Lett. 2004, 566:261-269.
47. McLean M.J., Gupta R.C., Dettbarn W.-D., Wamil A.W. Prophylactic and therapeutic efficacy of memantine against seizures produced by soman in the rat. Toxicol. Appl. Pharmacol. 1992, 112:95-103.
48. Miguel-Hidalgo J.J., Alvarez X.A., Cacabelos R., Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid (1-40). Brain Res. 2002, 958:210-221.
49. Milatovic D., Gupta R.C., Dekundy A., Montine T.J., Dettbarn W.-D. Carbofuran-induced oxidative stress in slow and fast skeletal muscles: Prevention by memantine and atropine. Toxicology 2005, 208:13-24.
50. Misztal M., Frankiewicz T., Parsons C.G., Danysz W. Learning deficits induced by chronic intraventricular infusion of quinolinic acid-Protection by MK-801 and memantine. Eur. J. Pharmacol. 1996, 296:1-8.
51. Möbius H.J. Memantine: Update on the current evidence. Int. J. Geriatr. Psychiatr. 2003, 18:S47-S54.
52. Möbius H.J., Stöffler A., Graham S.M. Memantine hydrochloride: Pharmacological and clinical profile. Drugs Today 2004, 40:685-695.
53. Moryl E., Danysz W., Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol. Toxicol. 1993, 72:394-397.
54. Muller W.E., Schroder H.C., Ushijima H., Dapper J., Bormann J. gp120 of HIV-1 induces apoptosis in rat cortical cell cultures: Prevention by memantine. Eur. J. Pharmacol. 1992, 226:209-214.
55. Orgogozo J.M., Rigaud A.S., Stöffler A., Möbius H.J., Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: A randomized, placebo-controlled trial (MMM 300). Stroke 2002, 33:1834-1839.
56. Pantev M., Ritter R., Görtelmeyer R. Clinical and behavioral evaluation in long-term care patients with mild to moderate dementia under memantine treatment. Z. Gerontol. Psychiatr. 1993, 6:103-117.
57. Parsons C.G., Gruner R., Rozental J., Millar J., Lodge D. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 1993, 32:1337-1350.
58. Parsons C.G., Danysz W., Bartmann A., Spielmanns P., Frankiewicz T., Hesselink M., Eilbacher B., Quack G. Amino-alkyl-cyclohexanes are novel uncompetitive NMDA receptor antagonists with strong voltage-dependency and fast blocking kinetics: In vitro and in vivo characterization. Neuropharmacology 1999, 38:85-108.
59. Parsons C.G., Danysz W., Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-A review of preclinical data. Neuropharmacology 1999, 38:735-767.
60. Parsons C.G., Frankiewicz T., Lazarewicz J.W., Gadamski R. Memantine enhances ischemic tolerance. Paper presented at the 53rd annual meeting of the American Academy of Neurology 2001.
61. Periclou A.P., Ventura D., Sherman T., Rao N., Abramowitz W.T. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann. Pharmacother. 2004, 38:1389-1394.
62. Peskind E.R., Potkin S.G., Pomara N., Ott B.R., McDonald S., Xie Y., Gergel I. Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: A randomized controlled trial. Int. J. Neuropsychopharmacol. 2004, 7(Suppl. 1):S207.
63. Popik P., Danysz W. Inhibition of reinforcing effects of morphine and motivational aspects of naloxoneprecipitated opioid withdrawal by N-methyl-D-aspartate receptor antagonist, memantine. J. Pharmacol. Exp. Ther. 1997, 280:854-865.
64. Popik P., Kozela E., Danysz W. Clinically available NMDA receptor antagonists memantine and dextromethorphan reverse existing tolerance to the antinociceptive effects of morphine in mice. Naunyn-Schmied. Arch. Pharmacol. 2000, 361:425-432.
65. Reisberg B., Doody R., Stöffler A., Schmitt F., Ferris S., Möbius H.J. Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 2003, 348:1333-1341.
66. Rieke J., Glaser A. Efficacy and tolerability of memantine in patients with dementia. Med. Welt. 1996, 47:251-254.
67. Rothman S.M., Olney J.W. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann. Neurol. 1986, 19:105-111.
68. Rothman S.M., Olney J.W. Excitotoxicity and the NMDA receptor-Still lethal after eight years. Trends. Neurosci. 1995, 18:57-58.
69. Rüther E., Glaser A., Bleich S., Degner D., Wiltfang J. A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine. Pharmacopsychiatry 2000, 33:103-108.
70. Schmitt B., Bernhardt T., Moeller H.J., Heuser I., Frölich L. Combination therapy in Alzheimer's disease: A review of current evidence. CNS Drugs 2004, 18:827-844.
71. Seif el Nasr M., Peruche B., Rossberg C., Mennel H.D., Krieglstein J. Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur. J. Pharmacol. 1990, 185:19-24.
72. Semenova S., Danysz W., Bespalov A. Low-affinity NMDA receptor channel blockers inhibit acquisition of intravenous morphine self-administration in naive mice. Eur. J. Pharmacol. 1999, 378:1-8.
73. Sobolevsky A.I., Koshelev S.G., Khodorov B.I. Interaction of memantine and amantadine with agonistunbound NMDA-receptor channels in acutely isolated rat hippocampal neurons. J. Physiol. 1998, 512(Pt. 1):47-60.
74. Stern Y., Sano M., Mayeux R. Long-term administration of oral physostigmine in Alzheimer's disease. Neurology 1988, 38:1837-1841.
75. Stojiljkovic M.P., Maksimovic M., Kilibarda V., Antonijevic B., Milovanovic Z.A., Jokanovic M., Boskovic B.D. Mamantine treatment improves antidotal efficacy of atropine, HI-6 and diazepam in rats poisoned with soman. Proc. Chem. Biol. Med. Treat. Symp. 2002.
76. Summers W.K., Majovski L.V., Marsh G.M., Tachiki K., Kling A. Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type. N. Engl. J. Med. 1986, 315:1241-1245.
77. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. J. Am. Med. Assoc. 2004, 291:317-324.
78. Terry A.V., Buccafusco J.J. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: Recent challenges and their implications for novel drug development. J. Pharmacol. Exp. Ther. 2003, 306:821-827.
79. Thal L.J., Masur D.M., Blau A.D., Fuld P.A., Klauber M.R. Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease. J. Am. Geriatr. Soc. 1989, 37:42-48.
80. Wenk G.L., Quack G., Möbius H.J., Danysz W. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci. 2000, 66:1079-1083.
81. Wilcock G., Möbius H.J., Stöffler A. A doubleblind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int. Clin. Psychopharmacol. 2002, 17:297-305.
82. Wilcock G.K. Memantine for the treatment of dementia. Lancet Neurol. 2003, 2:503-505.
83. Willard L.B., Hauss-Wegrzyniak B., Danysz W., Wenk G.L. The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp. Brain Res. 2000, 134:58-65.
84. Wimo A., Witthaus E., Rother M., Winblad B. Economic impact of introducing propentofylline for the treatment of dementia, in Sweden. Clin. Ther. 1998, 20:552-566.
85. Wimo A., Winblad B., Stöffler A., Wirth Y., Möbius H.J. Resource utilization and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 2003, 21:327-340.
86. Winblad B., Jelic V. Treating the full spectrum of dementia with memantine. Int. J. Geriatr. Psychiatr. 2003, 18:S41-S46.
87. Winblad B., Poritis N. Memantine in severe dementia: Results of the M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriatr. Psychiatr. 1999, 14:135-146.
88. Winblad B., Möbius H.J., Stöffler A. Glutamate receptors as a target for Alzheimer's disease-Are clinical results supporting the hope?. J. Neural. Transm. Suppl. 2002, 217-225.
89. Zajaczkowski W., Quack G., Danysz W. Infusion of (+)-MK-801 and memantine-Contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur. J. Pharmacol. 1996, 296:239-246.
90. Zajaczkowski W., Frankiewicz T., Parsons C.G., Danysz W. Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP. Neuropharmacology 1997, 36:961-971.